Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Cardiovascular Medicine
Published in: Current Treatment Options in Cardiovascular Medicine 7/2014

Open Access 01-07-2014 | Regenerative Medicine and Stem-cell Therapy (S Wu and P Hsieh, Section Editors)

Cardiac Stem Cell Therapy for Cardiac Repair

Authors: Kyung U. Hong, Ph.D., Roberto Bolli, M.D.

Published in: Current Treatment Options in Cardiovascular Medicine | Issue 7/2014

Login to get access

Opinion statement

The discovery of adult cardiac stem cells (CSCs) and their potential to restore functional cardiac tissue has fueled unprecedented interest in recent years. Indeed, stem-cell–based therapies have the potential to transform the treatment and prognosis of heart failure, for they have the potential to eliminate the underlying cause of the disease by reconstituting the damaged heart with functional cardiac cells. Over the last decade, several independent laboratories have demonstrated the utility of c-kit+/Lin- resident CSCs in alleviating left ventricular dysfunction and remodeling in animal models of acute and chronic myocardial infarction. Recently, the first clinical trial of autologous CSCs for treatment of heart failure resulting from ischemic heart disease (Stem Cell Infusion in Patients with Ischemic cardiOmyopathy [SCIPIO]) has been conducted, and the interim results are quite promising. In this phase I trial, no adverse effects attributable to the CSC treatment have been noted, and CSC-treated patients showed a significant improvement in ejection fraction at 1 year (+13.7 absolute units versus baseline), accompanied by a 30.2 % reduction in infarct size. Moreover, the CSC-induced enhancement in cardiac structure and function was associated with a significant improvement in the New York Heart Association (NYHA) functional class and in the quality of life, as measured by the Minnesota Living with Heart failure Questionnaire. These results are exciting and warrant larger, phase II studies. However, CSC therapy for cardiac repair is still in its infancy, and many hurdles need to be overcome to further enhance the therapeutic efficacy of CSCs.
Literature
1.
Go AS et al. Heart disease and stroke statistics—2013 update: a report from the American Heart Association. Circulation. 2013;127(1):e6–245.PubMedCrossRef
2.
Sanganalmath SK, Bolli R. Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ Res. 2013;113(6):810–34.PubMedCrossRef
3.
Beltrami AP et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell. 2003;114(6):763–76.PubMedCrossRef
4.
Rumyantsev PP. Interrelations of the proliferation and differentiation processes during cardiact myogenesis and regeneration. Int Rev Cytol. 1977;51:186–273.PubMed
5.
Cameron IL, Thrasher JD. Cellular and molecular renewal in the mammalian body. In: Cell biology. New York: Academic Press; 1971. p. xiv. 418 p.
6.
7.
Shafiq SA, Gorycki MA, Mauro A. Mitosis during postnatal growth in skeletal and cardiac muscle of the rat. J Anat. 1968;103(Pt 1):135–41.PubMedCentralPubMed
8.
Hsieh PC et al. Evidence from a genetic fate-mapping study that stem cells refresh adult mammalian cardiomyocytes after injury. Nat Med. 2007;13(8):970–4.PubMedCentralPubMedCrossRef
9.
Sohal DS et al. Temporally regulated and tissue-specific gene manipulations in the adult and embryonic heart using a tamoxifen-inducible Cre protein. Circ Res. 2001;89(1):20–5.PubMedCrossRef
10.
Novak A et al. Z/EG, a double reporter mouse line that expresses enhanced green fluorescent protein upon Cre-mediated excision. Genesis. 2000;28(3–4):147–55.PubMedCrossRef
11.
Morrison SJ et al. Identification of a lineage of multipotent hematopoietic progenitors. Development. 1997;124(10):1929–39.PubMed
12.
Weissman IL, Anderson DJ, Gage F. Stem and progenitor cells: origins, phenotypes, lineage commitments, and transdifferentiations. Annu Rev Cell Dev Biol. 2001;17:387–403.PubMedCrossRef
13.
14.
Linke A et al. Stem cells in the dog heart are self-renewing, clonogenic, and multipotent and regenerate infarcted myocardium, improving cardiac function. Proc Natl Acad Sci U S A. 2005;102(25):8966–71.PubMedCentralPubMedCrossRef
15.
16.
Anversa P et al. Life and death of cardiac stem cells: a paradigm shift in cardiac biology. Circulation. 2006;113(11):1451–63.PubMedCrossRef
17.
18.
Yang L et al. Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population. Nature. 2008;453(7194):524–8.PubMedCrossRef
19.
Wang X et al. The role of the sca-1+/CD31- cardiac progenitor cell population in postinfarction left ventricular remodeling. Stem Cells. 2006;24(7):1779–88.PubMedCrossRef
20.
Oh H et al. Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proc Natl Acad Sci U S A. 2003;100(21):12313–8.PubMedCentralPubMedCrossRef
21.
Hierlihy AM et al. The post-natal heart contains a myocardial stem cell population. FEBS Lett. 2002;530(1–3):239–43.PubMedCrossRef
22.
Pfister O et al. CD31- but not CD31+ cardiac side population cells exhibit functional cardiomyogenic differentiation. Circ Res. 2005;97(1):52–61.PubMedCrossRef
23.
Oyama T et al. Cardiac side population cells have a potential to migrate and differentiate into cardiomyocytes in vitro and in vivo. J Cell Biol. 2007;176(3):329–41.PubMedCentralPubMedCrossRef
24.
Messina E et al. Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ Res. 2004;95(9):911–21.PubMedCrossRef
25.
Smith RR et al. Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. Circulation. 2007;115(7):896–908.PubMedCrossRef
26.
Johnston PV et al. Engraftment, differentiation, and functional benefits of autologous cardiosphere-derived cells in porcine ischemic cardiomyopathy. Circulation. 2009;120(12):1075–83. 7 p following 1083.PubMedCentralPubMedCrossRef
27.
Wessels A, Perez-Pomares JM. The epicardium and epicardially derived cells (EPDCs) as cardiac stem cells. Anat Rec A: Discov Mol Cell Evol Biol. 2004;276(1):43–57.CrossRef
28.
29.
30.
31.
32.
Muller P et al. Cardiomyocytes of noncardiac origin in myocardial biopsies of human transplanted hearts. Circulation. 2002;106(1):31–5.PubMedCrossRef
33.
Thiele J et al. Mixed chimerism of cardiomyocytes and vessels after allogeneic bone marrow and stem-cell transplantation in comparison with cardiac allografts. Transplantation. 2004;77(12):1902–5.PubMedCrossRef
34.
Deb A et al. Bone marrow-derived cardiomyocytes are present in adult human heart: a study of gender-mismatched bone marrow transplantation patients. Circulation. 2003;107(9):1247–9.PubMedCrossRef
35.
Fazel S et al. Cardioprotective c-kit+ cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines. J Clin Invest. 2006;116(7):1865–77.PubMedCentralPubMedCrossRef
36.
Fujita J et al. Administration of granulocyte colony-stimulating factor after myocardial infarction enhances the recruitment of hematopoietic stem cell-derived myofibroblasts and contributes to cardiac repair. Stem Cells. 2007;25(11):2750–9.PubMedCrossRef
37.
Wang Y et al. Evidence for ischemia induced host-derived bone marrow cell mobilization into cardiac allografts. J Mol Cell Cardiol. 2006;41(3):478–87.PubMedCrossRef
38.
39.•
Ellison GM et al. Adult c-kit(pos) cardiac stem cells are necessary and sufficient for functional cardiac regeneration and repair. Cell. 2013;154(4):827–42. This study used a reversible myocardial injury model in conjuction with different genetic approaches to examine the contribution of endogenous c-kit+ cardiac stem cells to myocardial renewal. Using a genetic fate mapping approach to demonstrate that new cardiomyocytes originate from endogenous c-kit+ cardiac stem cells via direct differentiation.PubMedCrossRef
40.••
Bolli R et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet. 2011;378(9806):1847–57. This is the first interim report on the phase I clinical trial (SCIPIO) of c-kit+/Lin- cardiac stem cells.PubMedCentralPubMedCrossRef
41.•
Tang XL et al. Intracoronary administration of cardiac progenitor cells alleviates left ventricular dysfunction in rats with a 30-day-old infarction. Circulation. 2010;121(2):293–305. This study demonstrated that infusion of c-kit+/Lin- cardiac stem/progenitor cells is effective in improving the cardiac functions in a more clinically relevant setting using a chronic myocardial infarction model.PubMedCentralPubMedCrossRef
42.
Li Q, et al. Intracoronary administration of cardiac stem cells in mice: a new, improved technique for cell therapy in murine models. Basic Res Cardiol. 2011.
43.
Rota M et al. Local activation or implantation of cardiac progenitor cells rescues scarred infarcted myocardium improving cardiac function. Circ Res. 2008;103(1):107–16.PubMedCentralPubMedCrossRef
44.•
Bolli R et al. Intracoronary delivery of autologous cardiac stem cells improves cardiac function in a porcine model of chronic ischemic cardiomyopathy. Circulation. 2013;128(2):122–31. This study examined the therapeutic efficacy of c-kit/Lin- cardiac stem cells using a preclinical large animal model of ischemic cardiomyopathy.PubMedCrossRef
45.
Williams AR et al. Enhanced effect of combining human cardiac stem cells and bone marrow mesenchymal stem cells to reduce infarct size and to restore cardiac function after myocardial infarction. Circulation. 2013;127(2):213–23.PubMedCentralPubMedCrossRef
46.
47.
Rota M et al. Diabetes promotes cardiac stem cell aging and heart failure, which are prevented by deletion of the p66shc gene. Circ Res. 2006;99(1):42–52.PubMedCrossRef
48.
Kajstura J et al. Cardiac stem cells and myocardial disease. J Mol Cell Cardiol. 2008;45(4):505–13.PubMedCrossRef
49.
De Angelis A et al. Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation. 2010;121(2):276–92.PubMedCentralPubMedCrossRef
50.
Rona G et al. An infarct-like myocardial lesion and other toxic manifestations produced by isoproterenol in the rat. AMA Arch Pathol. 1959;67(4):443–55.PubMed
51.
Joyner AL, Zervas M. Genetic inducible fate mapping in mouse: establishing genetic lineages and defining genetic neuroanatomy in the nervous system. Dev Dyn. 2006;235(9):2376–85.PubMedCrossRef
52.
53.
54.
55.
van Berlo JH et al. c-kit+ cells minimally contribute cardiomyocytes to the heart. Nature. 2014;509(7500):337-41.
56.
Fischer KM et al. Enhancement of myocardial regeneration through genetic engineering of cardiac progenitor cells expressing Pim-1 kinase. Circulation. 2009;120(21):2077–87.PubMedCentralPubMedCrossRef
57.
Angert D et al. Repair of the injured adult heart involves new myocytes potentially derived from resident cardiac stem cells. Circ Res. 2011;108(10):1226–37.PubMedCentralPubMedCrossRef
58.
Dawn B et al. Cardiac stem cells delivered intravascularly traverse the vessel barrier, regenerate infarcted myocardium, and improve cardiac function. Proc Natl Acad Sci U S A. 2005;102(10):3766–71.PubMedCentralPubMedCrossRef
59.••
Chugh AR et al. Administration of cardiac stem cells in patients with ischemic cardiomyopathy: the SCIPIO trial: surgical aspects and interim analysis of myocardial function and viability by magnetic resonance. Circulation. 2012;126(11 Suppl 1):S54–64. This report provides more updated information on the progress of the SCIPIO trial and includes MRI-based analysis of cardiac stem cell-treated patients.PubMedCentralPubMedCrossRef
60.
Tang YL et al. Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector. J Am Coll Cardiol. 2005;46(7):1339–50.PubMedCrossRef
61.
62.
Reinecke H et al. Survival, integration, and differentiation of cardiomyocyte grafts: a study in normal and injured rat hearts. Circulation. 1999;100(2):193–202.PubMedCrossRef
63.
Toma C et al. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation. 2002;105(1):93–8.PubMedCrossRef
64.
65.
Schachinger V et al. Pilot trial on determinants of progenitor cell recruitment to the infarcted human myocardium. Circulation. 2008;118(14):1425–32.PubMedCrossRef
66.
Haider H, Ashraf M. Strategies to promote donor cell survival: combining preconditioning approach with stem cell transplantation. J Mol Cell Cardiol. 2008;45(4):554–66.PubMedCentralPubMedCrossRef
67.
Hong KU et al. A highly sensitive and accurate method to quantify absolute numbers of c-kit+ cardiac stem cells following transplantation in mice. Basic Res Cardiol. 2013;108(3):346.PubMedCentralPubMedCrossRef
68.
Forrester JS, Libby P. The inflammation hypothesis and its potential relevance to statin therapy. Am J Cardiol. 2007;99(5):732–8.PubMedCrossRef
69.
70.
Ma K et al. A Y chromosome gene family with RNA-binding protein homology: candidates for the azoospermia factor AZF controlling human spermatogenesis. Cell. 1993;75(7):1287–95.PubMedCrossRef
71.
Chai NN et al. Structure and organization of the RBMY genes on the human Y chromosome: transposition and amplification of an ancestral autosomal hnRNPG gene. Genomics. 1998;49(2):283–9.PubMedCrossRef
72.
Muraski JA et al. Pim-1 regulates cardiomyocyte survival downstream of Akt. Nat Med. 2007;13(12):1467–75.PubMedCrossRef
73.
Wang Z et al. Pim-1: a serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis. J Vet Sci. 2001;2(3):167–79.PubMed
74.
Wu JC et al. Molecular imaging of cardiac cell transplantation in living animals using optical bioluminescence and positron emission tomography. Circulation. 2003;108(11):1302–5.PubMedCrossRef
75.
Cottage CT et al. Increased mitotic rate coincident with transient telomere lengthening resulting from pim-1 overexpression in cardiac progenitor cells. Stem Cells. 2012;30(11):2512–22.PubMedCentralPubMedCrossRef
76.
Xu M, Millard RW, Ashraf M. Role of GATA-4 in differentiation and survival of bone marrow mesenchymal stem cells. Prog Mol Biol Transl Sci. 2012;111:217–41.PubMedCrossRef
77.
Huang W et al. Mesenchymal stem cells overexpressing CXCR4 attenuate remodeling of postmyocardial infarction by releasing matrix metalloproteinase-9. Stem Cells Dev. 2012;21(5):778–89.PubMedCentralPubMedCrossRef
78.
Mangi AA et al. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med. 2003;9(9):1195–201.PubMedCrossRef
79.
Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev. 1999;13(22):2905–27.PubMedCrossRef
80.
Fujio Y et al. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation. 2000;101(6):660–7.PubMedCentralPubMedCrossRef
81.
Melo LG et al. Gene therapy strategy for long-term myocardial protection using adeno-associated virus-mediated delivery of heme oxygenase gene. Circulation. 2002;105(5):602–7.PubMedCrossRef
82.
Vulapalli SR et al. Cardioselective overexpression of HO-1 prevents I/R-induced cardiac dysfunction and apoptosis. Am J Physiol Heart Circ Physiol. 2002;283(2):H688–94.PubMed
83.
McGinley LM et al. Mesenchymal stem cell survival in the infarcted heart is enhanced by lentivirus vector-mediated heat shock protein 27 expression. Hum Gene Ther. 2013;24(10):840–51.PubMedCrossRef
84.
Huang F et al. Overexpression of MicroRNA-1 improves the efficacy of mesenchymal stem cell transplantation after myocardial infarction. Cardiology. 2013;125(1):18–30.PubMedCrossRef
85.
Wang L et al. Protein kinase G1 alpha overexpression increases stem cell survival and cardiac function after myocardial infarction. PLoS ONE. 2013;8(3):e60087.PubMedCentralPubMedCrossRef
86.
Shan Y et al. Induction of the heme oxygenase-1 gene by metalloporphyrins. Arch Biochem Biophys. 2000;380(2):219–27.PubMedCrossRef
87.
Cai C et al. The heme oxygenase 1 inducer (CoPP) protects human cardiac stem cells against apoptosis through activation of the extracellular signal-regulated kinase (ERK)/NRF2 signaling pathway and cytokine release. J Biol Chem. 2012;287(40):33720–32.PubMedCentralPubMedCrossRef
88.
89.
Zafir A et al. Protein O-GlcNAcylation is a novel cytoprotective signal in cardiac stem cells. Stem Cells. 2013;31(4):765–75.PubMedCrossRef
90.
Ye L et al. Thymosin beta4 Increases the potency of transplanted mesenchymal stem cells for myocardial repair. Circulation. 2013;128(26 Suppl 1):S32–41.PubMedCrossRef
91.
Iso Y, et al. Priming with ligands secreted by human stromal progenitor cells promotes grafts of cardiac stem/progenitor cells after myocardial infarction. Stem Cells. 2013.
92.
Herrmann JL et al. Preconditioning mesenchymal stem cells with transforming growth factor-alpha improves mesenchymal stem cell-mediated cardioprotection. Shock. 2010;33(1):24–30.PubMedCrossRef
93.
Penna C et al. Pharmacologically active microcarriers influence VEGF-A effects on mesenchymal stem cell survival. J Cell Mol Med. 2013;17(1):192–204.PubMedCrossRef
94.
Pendergrass KD et al. Acute preconditioning of cardiac progenitor cells with hydrogen peroxide enhances angiogenic pathways following ischemia-reperfusion injury. Stem Cells Dev. 2013;22(17):2414–24.PubMedCrossRef
95.
96.
97.
Ebelt H et al. Cellular cardiomyoplasty: improvement of left ventricular function correlates with the release of cardioactive cytokines. Stem Cells. 2007;25(1):236–44.PubMedCrossRef
98.
Chimenti I et al. Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infarcted mice. Circ Res. 2010;106(5):971–80.PubMedCrossRef
99.
Yoon CH et al. Mechanism of improved cardiac function after bone marrow mononuclear cell therapy: role of cardiovascular lineage commitment. Circulation. 2010;121(18):2001–11.PubMedCrossRef
100.•
Behfar A et al. Guided cardiopoiesis enhances therapeutic benefit of bone marrow human mesenchymal stem cells in chronic myocardial infarction. J Am Coll Cardiol. 2010;56(9):721–34. This study showed that donor MSCs can be successfully primed or guided ex vivo to become cardiogenic, and that cardiogenic MSCs exhibit superior therapeutic efficacy against ischemic cardiomyopathy.PubMedCentralPubMedCrossRef
Metadata
Title
Cardiac Stem Cell Therapy for Cardiac Repair
Authors
Kyung U. Hong, Ph.D.
Roberto Bolli, M.D.
Publication date
01-07-2014
Publisher
Springer US
Published in
Current Treatment Options in Cardiovascular Medicine / Issue 7/2014
Print ISSN: 1092-8464
Electronic ISSN: 1534-3189
DOI
https://doi.org/10.1007/s11936-014-0324-3

Other articles of this Issue 7/2014

Current Treatment Options in Cardiovascular Medicine 7/2014 Go to the issue

Heart Failure (W Tang, Section Editor)

Contemporary Insights and Novel Treatment Approaches to Central Sleep Apnea Syndrome in Heart Failure

Regenerative Medicine and Stem-cell Therapy (S Wu and P Hsieh, Section Editors)

Pluripotent Stem Cell Derived Cardiomyocytes for Cardiac Repair

Vascular Disease (R Schainfeld, Section Editor)

The Role of Renal Denervation in the Treatment of Hypertension

Regenerative Medicine and Stem-cell Therapy (S Wu and P Hsieh, Section Editors)

Mesenchymal Stem Cell Therapy for Cardiac Repair

Regenerative Medicine and Stem-cell Therapy (S Wu and P Hsieh, Section Editors)

hiPSC Modeling of Inherited Cardiomyopathies

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits